

Supporting Info file

for

Synthesis and Characterization of Carbonyl Functionalized Organotellurium(IV) Derivatives

Puspendra Singh,^{*a} Mariya Khan,^b Andrew Duthie,^c Ray J. Butcher^d

^aDepartment of Chemistry, Dr. Shakuntala Misra National Rehabilitation University,
Lucknow, 226017, India.

^bDepartment of Chemistry, University of Lucknow, Lucknow, 226007, India.

^cDepartment of Chemistry, Indian Institute of Technology Kanpur, Kanpur, 208016, India

^dDepartment of Chemistry, Howard University, Washington DC20059, USA

*Corresponding Author, E-mail address: pushpendrasingh0612@gmail.com

INDEX

S.No.	Content	Page No.
	Index	S1-S3
1	Table S1. Crystal Data and Structure Refinement Details of 1, 4 and 5	S4
2	Table S2. Hydrogen bonds for 1, 4 and 5 (Å and °).	S5
3	Fig. S1 Crystal lattices of compound 1 showing helical structure through C-H---Cl (green) hydrogen bonding interactions.	S6
4	Fig. S2 Crystal lattices of compound 1 showing O-H---O (red), C-H---Cl and (green) hydrogen bonding interactions and Te---O (blue) & Te---Cl (black) secondary bonding interaction.	S7
5	Fig. S3 Crystal lattices of compound 1 showing π---π (brown) interaction.	S7
6	Fig. S4. Centrosymmetric dimeric unit in the crystal lattices of compound 1 through C-H---Cl (green) hydrogen bonding interactions.	S8
7	Fig. S5. Centrosymmetric dimeric unit in the crystal lattices of compound 4 through O-H---O (purple) hydrogen bonding interactions, Te---O (blue) secondary bonding interaction.	S8
8	Fig. S6. Supramolecular architecture along c axis of compound 4.	S9

9	Fig. S7. Supramolecular architecture along c axis of compound 4 .	S9
10	Fig. S8-S10 Supramolecular architectures in the crystal lattices of compound 5 .	S10-S11
11	Fig. S11 ^1H NMR spectrum of compound Ph[PhC(OH)CHC(O)CH ₂]TeCl ₂ (1) in CDCl ₃ .	S12
12	Fig. S12 Expanded aryl region of ^1H NMR spectrum of compound Ph[PhC(OH)CHC(O)CH ₂]TeCl ₂ (1) in CDCl ₃ .	S13
13	Fig. S13 ^{13}C NMR spectrum of compound Ph[PhC(OH)CHC(O)CH ₂]TeCl ₂ (1) in CDCl ₃ .	S14
14	Fig. S14 Expanded aryl region of ^{13}C NMR spectrum of compound Ph[PhC(OH)CHC(O)CH ₂]TeCl ₂ (1) in CDCl ₃ .	S15
15	Fig. S15 ^{125}Te NMR spectrum of compound Ph[PhC(OH)CHC(O)CH ₂]TeCl ₂ (1) in CDCl ₃ .	S16
16	Fig. S16 ^1H NMR spectrum of compound <i>p</i> -Tol[PhC(OH)CHC(O)CH ₂]TeCl ₂ (2) in CDCl ₃ .	S17
17	Fig. S17 Expanded aryl region of ^1H NMR spectrum of compound <i>p</i> -Tol[PhC(OH)CHC(O)CH ₂]TeCl ₂ (2) in CDCl ₃ .	S18
18	Fig. S18 ^{13}C NMR spectrum of compound <i>p</i> -Tol[PhC(OH)CHC(O)CH ₂]TeCl ₂ (2) in CDCl ₃ .	S19
19	Fig. S19 Expanded aryl region of ^{13}C NMR spectrum of compound <i>p</i> -Tol[PhC(OH)CHC(O)CH ₂]TeCl ₂ (2) in CDCl ₃ .	S20
20	Fig. S20 ^{125}Te NMR spectrum of compound <i>p</i> -Tol[PhC(OH)CHC(O)CH ₂]TeCl ₂ (2) in CDCl ₃ .	S21
21	Fig. S21 ^1H NMR spectrum of compound <i>I</i> -Nap[PhC(OH)CHC(O)CH ₂]TeCl ₂ (3) in CDCl ₃ .	S22
22	Fig. S22 Expanded aryl region of ^1H NMR spectrum of compound <i>I</i> -Nap[PhC(OH)CHC(O)CH ₂]TeCl ₂ (3) in CDCl ₃ .	S23
23	Fig. S23 ^{13}C NMR spectrum of compound <i>I</i> -Nap[PhC(OH)CHC(O)CH ₂]TeCl ₂ (3) in CDCl ₃ .	S24
24	Fig. S24 Expanded aryl region of ^{13}C NMR spectrum of compound <i>I</i> -Nap[PhC(OH)CHC(O)CH ₂]TeCl ₂ (3) in CDCl ₃ .	S25
25	Fig. S25 ^{125}Te NMR spectrum of compound <i>I</i> -Nap[PhC(OH)CHC(O)CH ₂]TeCl ₂ (3) in CDCl ₃ .	S26
26	Fig. S26 ^1H NMR spectrum of compound Mes[PhC(OH)CHC(O)CH ₂]TeCl ₂ (4).	S27
27	Fig. S27 Expanded aryl region of ^1H NMR spectrum of compound Mes[PhC(OH)CHC(O)CH ₂]TeCl ₂ (4).	S28
28	Fig. S28 ^{13}C NMR spectrum of compound Mes[PhC(OH)CHC(O)CH ₂]TeCl ₂ (4) in CDCl ₃ .	S29
29	Fig. S29 Expanded aryl region of ^{13}C NMR spectrum of compound Mes[PhC(OH)CHC(O)CH ₂]TeCl ₂ (4) in CDCl ₃ .	S30
30	Fig. S30 ^{125}Te NMR spectrum of compound Mes[PhC(OH)CHC(O)CH ₂]TeCl ₂ (4) in CDCl ₃ .	S31
31	Fig. S31 ^1H NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeCl ₂ (5).	S32
32	Fig. S32 Expanded aryl region of ^1H NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeCl ₂ (5).	S33
33	Fig. S33 ^{13}C NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeCl ₂ (5) in CDCl ₃ .	S34

34	Fig. S34 Expanded alkyl region of ^{13}C NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeCl ₂ (5) in CDCl ₃ .	S35
35	Fig. S35 ^1H NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeBr ₂ (6).	S36
36	Fig. S36 Expanded aryl region of ^1H NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeBr ₂ (6).	S37
37	Fig. S37 Expanded aryl region of ^{13}C NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeBr ₂ (6) in CDCl ₃ .	S38
38	Fig. S38 ^{125}Te NMR spectrum of compound Mes[CH ₃ (OH)CHC(O)CH ₂]TeBr ₂ (6) in CDCl ₃ .	S39

Table S1. Crystal Data and Structure Refinement Details of 1, 4 and 5

	1	4	5
empirical formula	C ₁₆ H ₁₄ Cl ₂ O ₂ Te	C ₁₉ H ₂₀ Cl ₂ O ₂ Te	C ₁₄ H ₁₈ Cl ₂ O ₂ Te
formula mass (g mol ⁻¹)	436.77	478.85	416.78
Temp (K)	100(2)	123(2)	100(2)
Wavelength, λ (Å)	0.710 73	0.710 73	0.710 73
cryst syst	monoclinic	monoclinic	monoclinic
cryst size (mm ³)	0.55 x 0.10 x 0.09	0.77 x 0.55 x 0.35	0.44 x 0.27 x 0.23
space group	P2 ₁ /c	P2 ₁ /c	P2 ₁
<i>a</i> (Å)	13.395(3)	8.7845(4)	8.389(5)
<i>b</i> (Å)	13.251(3)	19.5434(8)	12.312(5)
<i>c</i> (Å)	9.036(2)	11.0751(5)	8.461(5)
α (deg)	90	90	90.000(5)
β (deg)	98.213(4)	97.679(4)	116.320(5)
γ (deg)	90	90	90.000(5)
Volume (Å ³)	1587.5(7)	1884.3(1)	783.3(7)
Z	4	4	2
ρ_{calcd} (Mg m ⁻³)	1.827	1.688	1.767
abs coeff (mm ⁻¹)	2.211	1.871	2.235
F(000)	848	944	408
θ range (deg)	2.17-32.17	3.13-40.86	2.69-41.13
index ranges	-19 ≤ <i>h</i> ≤ 18, -18 ≤ <i>k</i> ≤ 19, -13 ≤ <i>l</i> ≤ 12	-15 ≤ <i>h</i> ≤ 16, -35 ≤ <i>k</i> ≤ 27, -20 ≤ <i>l</i> ≤ 19	-14 ≤ <i>h</i> ≤ 15, -22 ≤ <i>k</i> ≤ 22, -15 ≤ <i>l</i> ≤ 11
no. of rflns collected	12748	24302	11130
no. of indep rflns	5046	11990	7370
	(<i>R</i> (int) = 0.0344)	(<i>R</i> (int) = 0.0256)	(<i>R</i> (int) = 0.0295)
completeness to θ_{max} (%)	99.4	99.8	99.5
abs cor	semiempirical from equivalents	analytical	analytical
max. min. transmission	0.7464, 0.4720	0.593, 0.434	0.733, 0.564
refinement method	full-matrix least squares on F ²	full-matrix least squares on F ²	full-matrix least squares on F ²
No. of data/restraints/ parameters	5046/0/194	11990/0/224	7370/1/179
goodness of fit on F ²	1.040	1.088	1.019
final <i>R</i> indices [<i>I</i> > 2 σ(<i>I</i>)]	R1 = 0.0224, wR2 = 0.0570	R1 = 0.0345, wR2 = 0.0652	R1 = 0.0292, wR2 = 0.0569
<i>R</i> indices (all data)	R1 = 0.0255, wR2 = 0.0586	R1 = 0.0515, wR2 = 0.0707	R1 = 0.0344, wR2 = 0.0601
largest diff peak/hole (e Å ⁻³)	1.013/-0.549	0.687/-1.097	1.285/-0.985

Table S2. Hydrogen bonds for **1**, **4** and **5** (Å and °).

	D-H···A	d(D-H)	d(H···A)	d(D···A)	∠(DHA)	Symmetry
1	O(2)-H(2)···O(1)	0.80(3)	1.824(3)	2.559(2)	154(3)	
	C(9)-H(9A)···Cl(1)	0.95	2.667(1)	3.541(2)	153.1	x,-y+1/2,z-1/2
	C(6)-H(5A)···Cl(1)	0.95	2.785(1)	3.261(2)	111.9	-1+x, 0.5-y, -1.5+z
	C(9)-H(9A)···Cl(1)	0.95	2.667(1)	3.541(2)	153.1	1-x, 0.5+y, 0.5-z
	C(15)-H(15A)···Cl(2)	0.95	2.861(1)	3.783(2)	163.7	-1-x, y, -1+z
	C(2)-H(2A)···Cl(2)	0.95	2.853(1)	3.302(2)	110.1	1-x, 1-y, 1+z
	C(13)-H(13A)···O(1)	0.95	2.427(1)	3.339(2)	160.9	1-x, 1-y, 1-z
4	O(2)-H(2)···O(1)	0.75(2)	1.854(2)	2.541(1)	151(3)	
	O(2)-H(2)···O(1)	0.75(2)	2.419(2)	2.884(2)	121(2)	-x+1,-y+1,-z+1
	C(9)-H(9B)···Cl(2)	0.98	2.881(0)	3.629(2)	133.8	1 -x, 1-y. 1-z
	C(7)-H(7B)···Cl(1)	0.98	2.956(0)	3.741(2)	137.9	1 -x, 1-y. 1-z
	C(17)-H(17A)···Cl(1)	0.95	2.902(0)	3.717(2)	144.6	1 -x, 1-y. 1-z
5	O(2)-H(2)···O(1)	0.84	1.744(3)	2.498(3)	148.4	
	C(12)-H(12)···Cl(2)	0.95	2.911(1)	3.704(3)	141.8	1 -x+1,y-1/2,-z+1
	C(7)-H(7B)···Cl(2)	0.95	2.695(1)	3.531(3)	143.6	1-x, -0.5+y, 2-z
	C(14)-H(14A)···O(1)	0.98	2.522(2)	3.501(4)	176.4	-x+1,y-1/2,-z
	C(14)-H(14B)···Cl(1)	0.98	2.843(1)	3.803(4)	166.8	-x+2,y-1/2,-z+1
	C(9)-H(9A)···Cl(1)	0.98	2.872(1)	3.749(3)	149.6	-x+2,y-1/2,-z+1
	C(9)-H(9C)···Cl(1)	0.98	2.778(1)	3.462(3)	127.5	-x+2,y-1/2,-z+1




Fig. S1 Crystal lattices of compound 1 showing helical structure through C-H---Cl (green) hydrogen bonding interactions.




Fig. S2 Crystal lattices of compound **1** showing O-H---O (red), C-H---Cl and (green) hydrogen bonding interactions and Te---O (blue) & Te---Cl (black) secondary bonding interaction.




Fig. S3 Crystal lattices of compound **1** showing π---π (brown) interaction.




Fig. S4. Centrosymmetric dimeric unit in the crystal lattices of compound **1** through C-H---Cl (green) hydrogen bonding interactions.




Fig. S5. Centrosymmetric dimeric unit in the crystal lattices of compound **4** through O-H---O (purple) hydrogen bonding interactions, Te---O (blue) secondary bonding interaction.




Fig. S6. Centrosymmetric dimeric unit in the crystal lattices of compound **4** through C-H---Cl (green) hydrogen bonding interactions.




Fig. S7. Supramolecular architecture along *c* axis of compound **4**.




Fig. S8. Supramolecular architectures in the crystal lattices of compound 5 through O-H---O (purple) and C-H---Cl (green) hydrogen bonding interactions and Te---O (blue) secondary bonding interaction.




Fig. S9. Supramolecular architectures in the crystal lattices of compound 5 through O-H---O (purple) and C-H---Cl (green) hydrogen bonding interactions.




Fig. S10. Supramolecular architectures in the crystal lattices of compound **5** through O-H---O (purple) and C-H---Cl (green) hydrogen bonding interactions.




Fig. S11. ¹H NMR spectrum of compound Ph[PhC(OH)CHC(O)CH₂]TeCl₂ (**1**) in CDCl₃.




Fig. S12. Expanded aryl region of ^1H NMR spectrum of compound $\text{Ph}[\text{PhC(OH)}\text{CHC(O)}\text{CH}_2]\text{TeCl}_2$ (**1**) in CDCl_3 .




Fig. S13. ^{13}C NMR spectrum of compound $\text{Ph}[\text{PhC(OH)}\text{CHC(O)}\text{CH}_2]\text{TeCl}_2$ (**1**) in CDCl_3 .




Fig. S14. Expanded aryl region of ^{13}C NMR spectrum of compound Ph[PhC(O)CHC(O)CH₂]TeCl₂ (**1**) in CDCl₃.




Fig. S15. ^{125}Te NMR spectrum of compound $\text{Ph}[\text{PhC(OH)}\text{CHC(O)}\text{CH}_2]\text{TeCl}_2$ (**1**) in CDCl_3 .




Fig. S16. ¹H NMR spectrum of compound *p*-Tol[PhC(OH)CHC(O)CH₂]TeCl₂ (**2**) in CDCl₃.




Fig. S17. Expanded aryl region of ^1H NMR spectrum of compound *p*-Tol[PhC(OH)CHC(O)CH₂]TeCl₂ (**2**) in CDCl₃.




Fig. S18. ^{13}C NMR spectrum of compound $p\text{-Tol}[\text{PhC(OH)}\text{CHC(O)}\text{CH}_2]\text{TeCl}_2$ (**2**) in CDCl_3 .




Fig. S19. Expanded aryl region of ^{13}C NMR spectrum of compound *p*-Tol[PhC(OH)CHC(O)CH₂]TeCl₂ (**2**) in CDCl₃.




Fig. S20. ^{125}Te NMR spectrum of compound $p\text{-Tol}[\text{PhC(OH)}\text{CHC(O)}\text{CH}_2]\text{TeCl}_2$ (**2**) in CDCl_3 .




Fig. S21. ^1H NMR spectrum of compound *l*-Nap[PhC(OH)CHC(O)CH₂]TeCl₂ (**3**) in CDCl₃.

MK-033




Fig. S22. Expanded aryl region of ¹H NMR spectrum of compound *I*-Nap[PhC(OH)CHC(O)CH₂]TeCl₂ (**3**) in CDCl₃.




Fig. S23. ^{13}C NMR spectrum of compound *I*-Nap[PhC(OH)CHC(O)CH₂]TeCl₂ (**3**) in CDCl₃.




Fig. S24. Expanded aryl region of ^{13}C NMR spectrum of compound *1*-Nap[PhC(OH)CHC(O)CH₂]TeCl₂ (**3**) in CDCl₃.




Fig. S25. ^{125}Te NMR spectrum of compound *I*-Nap[PhC(OH)CHC(O)CH₂]TeCl₂ (**3**) in CDCl₃.

MK-031




Fig. S26. ^1H NMR spectrum of compound Mes[PhC(OH)CHC(O)CH₂]TeCl₂ (**4**).

MK-031




Fig. S27. Expanded aryl region of ¹H NMR spectrum of compound Mes[PhC(OH)CHC(O)CH₂]TeCl₂ (**4**).




Fig. S28. ^{13}C NMR spectrum of compound Mes[PhC(OH)CHC(O)CH₂]TeCl₂ (**4**) in CDCl₃.




Fig. S29. Expanded aryl region of ^{13}C NMR spectrum of compound Mes[PhC(O)CHC(O)CH₂]TeCl₂ (**4**) in CDCl₃.




Fig. S30. ^{125}Te NMR spectrum of compound Mes[PhC(OH)CHC(O)CH₂]TeCl₂ (**4**) in CDCl₃.




Fig. S31. ¹H NMR spectrum of compound Mes[CH₃(OH)CHC(O)CH₂]TeCl₂ (**5**).




Fig. S32. Expanded aryl region of ^1H NMR spectrum of compound $\text{Mes}[\text{CH}_3(\text{OH})\text{CHC}(\text{O})\text{CH}_2]\text{TeCl}_2$ (**5**).




Fig. S33. ^{13}C NMR spectrum of compound Mes[CH₃(OH)CHC(O)CH₂]TeCl₂ (**5**) in CDCl₃.




Fig. S34. Expanded alkyl region of ^{13}C NMR spectrum of compound Mes[CH₃(OH)CHC(O)CH₂]TeCl₂ (**5**) in CDCl₃.

MK-83

NAME 8685.MK83
EXPNO 10
PROCNO 1
Date 20150520
Time 13:06
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zg30
TD 65536
SOLVENT CDCl₃
NS 64
DS 2
SWH 7500.000 Hz
FIDRES 0.114441 Hz
AQ 4.3691168 sec
RG 362
DW 66.667 usec
DE 6.50 usec
TE 300.0 K
D1 1.0000000 sec
TDO 1

===== CHANNEL f1 =====
NUC1 1H
P1 11.60 usec
PL1 -1.00 dB
PL1W 15.02081871 W
SF01 300.1324010 MHz
SI 32768
SF 300.1300066 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




Fig. S35. ^1H NMR spectrum of compound Mes[CH₃(OH)CHC(O)CH₂]TeBr₂ (**6**).




Fig. S36. ¹H NMR spectrum of compound Mes[CH₃(OH)CHC(O)CH₂]TeBr₂ (**6**).




Fig. S37. Expanded aryl region of ^{13}C NMR spectrum of compound Mes[CH₃(OH)CHC(O)CH₂]TeBr₂ (**6**) in CDCl₃.




Fig. S38. ^{125}Te NMR spectrum of compound Mes[CH₃(OH)CHC(O)CH₂]TeBr₂ (**6**) in CDCl₃.